Filtered By:
Condition: Atrial Fibrillation
Education: Learning
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 198 results found since Jan 2013.
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Machine Learning-Based Prediction of Atrial Fibrillation Risk Using Electronic Medical Records in Older Aged Patients
Atrial fibrillation (AF) is an independent risk factor that increases the risk of stroke 5-fold. The purpose of our study was to develop a 1-year new-onset AF predictive model by machine learning based on 3-year medical information without electrocardiograms in our database to identify AF risk in older aged patients. We developed the predictive model according to the Taipei Medical University clinical research database electronic medical records, including diagnostic codes, medications, and laboratory data.
Source: The American Journal of Cardiology - May 18, 2023 Category: Cardiology Authors: Yung-Ta Kao, Chun-Yao Huang, Yu-Ann Fang, Ju-Chi Liu, Tzu-Hao Chang Source Type: research
Appropriate Use Criteria of Left Atrial Appendage Closure Devices: Latest Evidences
Expert Rev Med Devices. 2023 May 1. doi: 10.1080/17434440.2023.2208748. Online ahead of print.ABSTRACTAtrial fibrillation is the most common arrythmia and it is linked to an increased risk of stroke. Even if anticoagulation therapy reduces the rate of stroke the benefits of this therapy have to been balanced with the increased risk of hemorrhagic event. Left atrial appendage closure is a valid alternative to long term anticoagulation in patients with atrial fibrillation and high hemorrhagic risk. Actually new devices with different features have been tested and introduced progressively in the clinical practice. Improvement...
Source: Expert Review of Medical Devices - May 2, 2023 Category: Medical Devices Authors: Fabrizio Guarracini Eleonora Bonvicini Alberto Preda Marta Martin Simone Muraglia Giulia Casagranda Marianna Mochen Alessio Coser Silvia Quintarelli Stefano Branzoli Roberto Bonmassari Massimiliano Marini Patrizio Mazzone Source Type: research
Automatic Segmentation of the Left Atrium from Computed Tomography Angiography Images
Ann Biomed Eng. 2023 Mar 8. doi: 10.1007/s10439-023-03170-9. Online ahead of print.ABSTRACTThe left atrial appendage (LAA) causes 91% of thrombi in atrial fibrillation patients, a potential harbinger of stroke. Leveraging computed tomography angiography (CTA) images, radiologists interpret the left atrium (LA) and LAA geometries to stratify stroke risk. Nevertheless, accurate LA segmentation remains a time-consuming task with high inter-observer variability. Binary masks of the LA and their corresponding CTA images were used to train and test a 3D U-Net to automate LA segmentation. One model was trained using the entire un...
Source: Annals of Biomedical Engineering - March 8, 2023 Category: Biomedical Engineering Authors: Amaan Kazi Sage Betko Anish Salvi Prahlad G Menon Source Type: research
Deep-Learning for Epicardial Adipose Tissue Assessment With Computed Tomography: Implications for Cardiovascular Risk Prediction
CONCLUSIONS: Automated assessment of EAT volume is possible in CCTA, including in patients who are technically challenging; it forms a powerful marker of metabolically unhealthy visceral obesity, which could be used for cardiovascular risk stratification.PMID:36881425 | DOI:10.1016/j.jcmg.2022.11.018
Source: Atherosclerosis - March 7, 2023 Category: Cardiology Authors: Henry W West Muhammad Siddique Michelle C Williams Lucrezia Volpe Ria Desai Maria Lyasheva Sheena Thomas Katerina Dangas Christos P Kotanidis Pete Tomlins Ciara Mahon Attila Kardos David Adlam John Graby Jonathan C L Rodrigues Cheerag Shirodaria John Dean Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
IJERPH, Vol. 20, Pages 2359: Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran
hi-Jie Lu
The new generation of nonvitamin K antagonists are broadly applied for stroke prevention due to their notable efficacy and safety. Our study aimed to develop a suggestive utilization of dabigatran through an integrated machine learning (ML) decision-tree model. Participants taking different doses of dabigatran in the Randomized Evaluation of Long-Term Anticoagulant Therapy trial were included in our analysis and defined as the 110 mg and 150 mg groups. The proposed scheme integrated ML methods, namely naive Bayes, random forest (RF), classification and regression tree (CART), and extreme gradient boosting (XG...
Source: International Journal of Environmental Research and Public Health - January 29, 2023 Category: Environmental Health Authors: Yung-Chuan Huang Yu-Chen Cheng Mao-Jhen Jhou Mingchih Chen Chi-Jie Lu Tags: Article Source Type: research
Prediction of incident atrial fibrillation in post-stroke patients using machine learning: a French nationwide study
ConclusionsML algorithms predict incident AF post-stroke with a better ability than previously developed clinical scores.Graphic AbstractAF: atrial fibrillation; DNN: deep neural network; IS: ischemic stroke; KNN: K-nearest neighbors; LR: logistic regression; RFC: random forest classifier; XGBoost: extreme gradient boosting
Source: Clinical Research in Cardiology - December 17, 2022 Category: Cardiology Source Type: research
Prediction of incident cardiovascular events using machine learning and CMR radiomics
ConclusionsRadiomics features may provide incremental predictive value over VRF and CMR indices in the prediction of incident CVDs.Key Points•Prediction of incident atrial fibrillation, heart failure, stroke, and myocardial infarction using machine learning techniques.•CMR radiomics, vascular risk factors, and standard CMR indices will be considered in the machine learning models.•The experiments show that radiomics features can provide incremental predictive value over VRF and CMR indices in the prediction of incident cardiovascular diseases.
Source: European Radiology - December 13, 2022 Category: Radiology Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
